Finance

Beta
Lists
WST:NYSE
West Pharmaceutical Services Inc
$317.32
+0.34%
(+1.06) 1D
$317.32
0.00% (0.00)
After hours
Closed: Jun 4, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WST...
Open
$319.87
High
$321.50
Low
$315.09
Mkt. cap
22.42B
Avg. vol.
902.73K
Volume
0.00
Dividend
0.28%
Quarterly dividend
$0.22
Ex-dividend date
Apr 29, 2026
P/E ratio
42.42
52-wk high
$330.88
52-wk low
$206.80
EPS
$7.48
Beta
1.18
Shares outstanding
70.65M
No. of employees
11K
Open
$319.87
High
$321.50
Low
$315.09
Mkt. cap
22.42B
Avg. vol.
902.73K
Volume
0.00
Dividend
0.28%
Quarterly dividend
$0.22
Ex-dividend date
Apr 29, 2026
P/E ratio
42.42
52-wk high
$330.88
52-wk low
$206.80
EPS
$7.48
Beta
1.18
Shares outstanding
70.65M
No. of employees
11K
Analyst outlook
Analyst Ratings
Based on 8 analysts giving stock ratings to WST in the past 3 months
Strong Buy
Buy
6
Hold
2
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current $317.32
$400.00 (+26.06%)
Average
$355.00 (+11.87%)
Lowest
$310.00 (-2.31%)
News stories
From sources across the web
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees10.8K
Founded1923
HeadquartersWest Whiteland Township, Pennsylvania, United States
SectorHealth care
Websitewestpharma.com
Last report
Apr 23, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.13 / $1.68
+27.07%beat
Revenue / Est. (USD)
844.90M / 779.37M
+8.41%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
766.50M
804.60M
805.00M
844.90M
Cost of goods sold
492.60M
510.30M
501.10M
548.50M
Cost of revenue
492.60M
510.30M
501.10M
548.50M
Research and development expenses
19.10M
17.10M
21.80M
15.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94.50M
101.10M
107.50M
99.50M
Operating expense
113.90M
118.50M
129.70M
113.10M
Total operating expenses
606.50M
628.80M
630.80M
661.60M
Operating income
160.00M
175.80M
174.20M
183.30M
Other non operating income
-200.00K
-200.00K
600.00K
-200.00K
EBT including unusual items
162.00M
174.00M
165.40M
183.50M
EBT excluding unusual items
166.60M
179.50M
181.20M
188.60M
Income tax expense
30.20M
34.00M
33.30M
44.70M
Effective tax rate
18.64%
19.54%
20.13%
24.36%
Other operating expenses
300.00K
300.00K
400.00K
-2.20M
Net income
131.80M
140.00M
132.10M
138.80M
Net profit margin
17.20%
17.40%
16.41%
16.43%
Earnings per share
1.84
1.96
2.04
2.13
Interest and investment income
3.60M
4.70M
5.30M
5.10M
Interest expense
-100.00K
-200.00K
-
-1.90M
Net interest expenses
3.50M
4.50M
5.30M
3.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
201.40M
218.80M
221.20M
228.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer